Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study

BACKGROUND: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in patients undergoing cytoreductive surgery (CRS) and HI...

Descripción completa

Detalles Bibliográficos
Autores principales: Benzaquen, Ella, Wang, Yifan, Wiseman, Stephanie, Rosenfeld, Velka, Sideris, Lucas, Dubé, Pierre, Pelletier, Jean-Sebastien, Vanounou, Tsafrir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Joule Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064255/
https://www.ncbi.nlm.nih.gov/pubmed/33651573
http://dx.doi.org/10.1503/cjs.001619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064255/
https://www.ncbi.nlm.nih.gov/pubmed/33651573
http://dx.doi.org/10.1503/cjs.001619

Ejemplares similares